SINGAPORE PERSPECTIVE

Singapore, May 16, 2026. The city-state, whose health strategy was forged by the lessons of the 2003 SARS outbreak, is observing with rigor the development of the new Ebola outbreak confirmed in Ituri Province, in eastern Democratic Republic of Congo. The Straits Times reported the announcement from the Congolese Ministry of Health: 246 suspected cases recorded, 80 deaths registered, and eight laboratory-confirmed cases in the health zones of Rwampara, Mongwalu, and Bunia.

What particularly captures the attention of Singapore's observers is the nature of the identified strain. Samples analyzed in Kinshasa revealed the presence of the Bundibugyo variant—not the Zaire strain, the most well-known and frequent strain. Jean-Jacques Muyembe, Congolese virologist and co-discoverer of Ebola and director of the National Institute of Biomedical Research, warned Reuters that this difference was fundamental: the treatments and vaccines currently available were developed against the Zaire strain. Against Bundibugyo, the existing medical arsenal loses much of its effectiveness.

The presumed index case is a nurse who died at the Evangelical Medical Center in Bunia after presenting with fever, hemorrhages, vomiting, and severe weakness—a clinical presentation characteristic of the disease. Africa CDC, which confirmed the epidemic on Friday morning with a provisional toll of 65 deaths, immediately convened an emergency meeting bringing together the DRC, Uganda, South Sudan, and international partners to strengthen cross-border surveillance.

This regional mobilization is directly linked to the geography of the epidemic. The affected zones border Uganda and South Sudan, in a context marked by intense mobility linked to mining activities. Africa CDC explicitly mentioned the risk related to "intense population movements" and the "urban context of Bunia and Rwampara." This risk has already materialized: Uganda reported the death in Kampala of a Congolese national carrying the Bundibugyo variant, a case declared as imported without confirmed local transmission at this stage.

The WHO, which had been informed of suspected cases on May 5 and deployed a team on the ground, did not obtain laboratory confirmation until May 15—the first field samples having tested negative. Director-General Tedros Adhanom Ghebreyesus announced at a press conference the release of 500,000 dollars from the organization's contingency fund, intended for epidemiological surveillance, contact tracing, laboratory testing, and clinical care. The total number of laboratory-confirmed positive cases now stands at 13.